Abstract:We read with interest the study by Lin et al1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar that reported a high rate of false-positive diagnoses of small bowel bacterial overgrowth (SBBO) by glucose hydrogen breath testing (HBT) with nearly 50% of diagnoses being false-positives caused by rapid transit and early colonic fermentation of unabsorbed substrate. This effect was most marked in patients with previous upper gastrointestinal surgery (65% vs 13% in patients without prior surgery). Lactulose is a poorly absorbed, fermentable disaccharide that has also been used to detect SBBO by HBT. The lactulose HBT is said to be more sensitive than glucose HBT or bacterial culture of jejunal aspirates (the “reference standard”) because it can detect cases with distal SBBO and pathologic bacterial strains that do not culture well.2Schiller L.R. Curr Gastroenterol Rep. 2007; 9: 373-377Crossref PubMed Scopus (32) Google Scholar Unfortunately, clinical studies have also shown that lactulose HBT does not provide a reliable diagnosis of SBBO because of variability in orocecal transit time.1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar, 3Corazza G.R. et al.Gastroenterology. 1990; 98: 302-309Abstract Full Text PDF PubMed Google Scholar, 4Yu D. et al.Gut. 2011; 60: 334-340Crossref PubMed Scopus (202) Google Scholar To address this limitation, investigators have combined lactulose HBT with concurrent scintigraphic assessment of orocecal transit. The diagnosis of SBBO is confirmed if there is a physiologically relevant increase in breath hydrogen well before labeled substrate enters the caecum. Using this approach, Zhao et al5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar found that the combined test identified SBBO in at least 1 in 3 patients with irritable bowel syndrome (IBS) and also that the presence of bacteria in the small bowel was associated with increased risk of lactose intolerance in a population with lactase deficiency. Consistent with the findings of Lin et al,1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar the orocecal transit time was similar in those with and without SBBO (63 min vs 56 min; P = .071).5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar Moreover there was no difference in orocecal transit time between patients with IBS and healthy control subjects (74 min vs 68 min; P = .433).5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar Thus, it was only the presence of abnormal findings on combined lactulose HBT and scinitigraphy that identified possible SIBO in the patients with IBS. Subsequently, a prospective study by the same group demonstrated that the results of the combined test can also guide therapy. Beneficial effects of antibiotic treatment (rifaximin) on IBS symptoms were observed more often in SBBO-positive than SBBO-negative patients (64% vs 15%; P = .018).6Zhao J. et al.Neurogastroenterol Motil. 2014; 26: 794-802Crossref PubMed Scopus (50) Google Scholar In particular, patients with IBS with diarrhea and SBBO frequently reported improvement in abdominal symptoms including stool frequency and consistency.6Zhao J. et al.Neurogastroenterol Motil. 2014; 26: 794-802Crossref PubMed Scopus (50) Google Scholar Taken together, as argued by Sellin7Sellin J.H. Clin Gastroenterol Hepatol. 2016; 14: 209-211Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar in his editorial, these findings suggest that lactulose HBT with concurrent scintigraphy provides an accurate diagnostic test for SBBO. If this is not available routinely for reasons of cost, then patients with abnormal results from glucose or lactulose HBT should be considered for a confirmatory test with concurrent scintigraphy to distinguish SBBO from rapid transit accompanied by early colonic fermentation. The use of serial tests (ie, HBT followed by scintigraphy) may be less ideal because of relatively high day-to-day variation in orocecal transit time. Looking ahead, the results of the combined lactulose HBT with concurrent scintigraphy investigation may help to identify the causes of IBS symptoms and to direct antibiotic therapy to patients that are likely to benefit. This would be welcome because the number needed to treat was >10 in unselected patients with IBS given rifaximin in the TARGET study.8Pimentel M. et al.Dig Dis Sci. 2011; 56: 2067-2072Crossref PubMed Scopus (76) Google Scholar If the outcome data of Zhao et al were confirmed, the proposed approach could reduce this to a number needed to treat of ∼3–4 and, at the same time, reduce the unnecessary and ineffective use of antibiotics in patients with IBS without SBBO. Scintigraphy Demonstrates High Rate of False-positive Results From Glucose Breath Tests for Small Bowel Bacterial OvergrowthClinical Gastroenterology and HepatologyVol. 14Issue 2PreviewBreath tests for hydrogen and/or methane are used to detect small bowel bacterial overgrowth (SBBO), but false-positive results can arise from clinical conditions that accelerate small bowel transit and deliver unabsorbed glucose to the colon. We investigated the prevalence of false-positive results from glucose breath tests by also evaluating patients with scintigraphy. Full-Text PDF ReplyClinical Gastroenterology and HepatologyVol. 14Issue 10PreviewThe comments by Deng et al on recent literature point out the necessity of using concurrent scintigraphic assessment of orocecal transit time when attempting to attribute increases in breath hydrogen or methane levels after lactulose ingestion to small-bowel bacterial overgrowth. We agree, but want to emphasize the importance of the scintigraphy protocol used to avoid a false diagnosis of bacterial overgrowth. In the studies cited by Deng et al, the goal was to distinguish, from among groups of patients with putative irritable bowel syndrome or lactase deficiency, patients whose symptoms might result from bacterial overgrowth. Full-Text PDF

Mo1545 DISTINCT TREATMENT CHOICES BETWEEN PRIMARY CARE GI PHYSICIANS AND GENERAL RACTITIONERS: A REAL WORLD CROSS-SECTIONAL STUDY

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

Clinical Value of Radionuclide Small Intestine Transit Time Measurement Combined with Lactulose Hydrogen Breath Test for the Diagnosis of Bacterial Overgrowth in Irritable Bowel Syndrome.

The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation

Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines

Clinical Features of Irritable Bowel Syndrome with Small Intestinal Bacterial Overgrowth and a Preliminary Study of Effectiveness of Rifaximin

Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth.

Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity

Tu2066 Prevalence of Irritable Bowel Syndrome in China: Joint Effects of Psychiatric Morbidity with Life Event Stress and Lactose Intake

Hydrogen Breath Testing with Measurement of Orocecal Transit for Diagnosis of Small Bowel Bacterial Overgrowth.

Su2034 Diagnosis of Small Intestinal Bacterial Overgrowth by Lactulose Hydrogen Breath Test with Scintigraphic Oro-Caecal Transit Test: Methodological Validation of Diagnostic Criteria in Healthy Controls and Patients with Diarrhea Predominant Irritable Bowel Syndrome

Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)

Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia

Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders

The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation

Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis

Defining Small Intestinal Bacterial Overgrowth by Culture and High Throughput Sequencing

Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats.

Treatment of small intestinal bacterial overgrowth: Conventional antibiotic therapy and alternative therapy - probiotics and low FODMAP diet

Fecal Coprococcus, hidden behind abdominal symptoms in patients with small intestinal bacterial overgrowth